Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Smith & Nephew on track to deliver full-year guidance as third-quarter revenue rises thanks to strong demand in US, emerging markets

In a brief trading update, the FTSE 100-listed medical technology group said its third-quarter revenue was US$1.169bn, up 2% on a reported basis and 3% on an underlying basis
Knees
S&N forecast that its 2018 underlying revenue would be in the lower half of the 2% to 3% range

Smith & Nephew PLC (LON:SN.) shares rose on Thursday after the medical technology firm said it is on track to deliver in its full-year guidance as it reported solid growth in third-quarter revenue thanks to strong demand in the US and emerging markets.

In a brief trading update, the FTSE 100-listed group said its third-quarter revenue was US$1.169bn, up 2% on a reported basis and 3% on an underlying basis.

READ: New Smith & Nephew boss gives bullish assessment of artificial hip maker’s health

The firm said quarterly underlying revenue growth was 4% in the US and 10% in emerging markets.

The artificial knees and hips maker forecast that its 2018 underlying revenue would be in the lower half of the 2% to 3% guidance range, but said it expected its trading profit margin to be above last year's thanks to improved cost controls and a favourable legal settlement.

Namal Nawana, S&N’s recently appointed chief executive officer, said: "These results were achieved whilst successfully redesigning how we will run the company. There is still more to do, and I am pleased with the pace of progress and engagement across the organisation."

Hips and knees growth

In a note to clients, analysts at UBS commented: “Both Hips & Knee growth was 4% underlying, in line with the acceleration management expected but ahead of cons in our view.

“However weakness in Europe and Wound Bioactives (-7%) means that management now guides to the bottom end of the previous range of 2-3% underlying revenue growth.”

They added: “Investors are looking for cost control, but revenue guidance may be a focus.”

UBS reiterated a ‘neutral’ stance and 1,340p per share 12-month price target on Smith & Nephew.

In late morning trading in London, the bluechip stock was 6.7% higher at 1,359p.

 -- Adds analyst comment, share price --

View full SN. profile View Profile

Smith & Nephew PLC Timeline

Related Articles

Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use